US Patent Issued to Novartis on Aug. 11 for "Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof" (Swiss, American Inventors)

ALEXANDRIA, Va., Aug. 12 -- United States Patent no. 12,703,762, issued on Aug. 11, was assigned to Novartis AG (Basel, Switzerland).

"Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof" was invented by Stefan Ewert (Basel, Switzerland), Andrew Green (Basel, Switzerland) and Alexander Wolfgang Koch (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to reversal agents, which specifically bind to anti-Factor XI and/or anti-Factor XIa antibodies (e.g., NOV1401), and reverse one or more anticoagulant effects of the anti-Factor XI and/or anti-Factor XIa antibodies (e.g., NOV1401), as well as to methods of use thereof, such as methods for reversi...